Improving survival for children with brain tumors using targeted therapies.
Official title: Pediatric brain tumors: Improving survival through integration of clinical molecular diagnostics and biologically targeted therapies into clinical trials
Funded at Seattle Children's Hospital · NIH-11046518 · Data updated 2026-11-12
This study is looking to improve the chances of survival for kids with brain tumors by using new treatments that are specially designed based on the unique biology of their tumors, while also working to minimize the side effects of standard cancer treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 21, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $175,338 |
| NIH project number | 5R50CA275857-03 |
| Project ID | NIH-11046518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who have been diagnosed with central nervous system tumors.
✕Less likely to help
Patients with brain tumors who are older than 11 years or those with non-CNS tumors may not benefit from this research.
What this research studies
This research aims to enhance the survival rates of children diagnosed with central nervous system tumors by integrating clinical molecular diagnostics with biologically targeted therapies in clinical trials. The approach involves developing novel treatments based on a deep understanding of the molecular mechanisms driving these tumors. By collaborating with national and international clinical trial networks, the research seeks to create a framework for sharing genomic data and facilitating innovative treatment options. This initiative is particularly focused on reducing the long-term side effects associated with traditional cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and reduced treatment-related toxicity for children with brain tumors.
How similar studies have gone: Previous research has shown promising results in using targeted therapies for pediatric cancers, indicating a potential for success in this novel approach.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Leary, Sarah Elisabeth Sherr — Seattle Children's Hospital
- Study coordinator: Leary, Sarah Elisabeth Sherr
Related research
Other NIH-funded projects on the same topics.
-
ONC206 for children with brain tumors: a first-in-children trial
A first-in-children trial will test the safety and early signs of effectiveness of ONC206, taken by mouth, in kids with malignant brain tumors like diffuse midline gliomas.
-
ONC206 for children with malignant brain tumors
A first-in-children trial tests the safety and early effectiveness of a pill that can cross the brain barrier to treat pediatric brain tumors.
-
ONC206 for children with dangerous brain tumors
A first-in-children study tests the safety and early effectiveness of an oral drug, ONC206, for kids with high-risk brain tumors that have spread or recurred.
-
Oral bacteria and brain metastasis: how the mouth may influence brain tumors
A study exploring how oral microbes may affect brain metastases and patient outcomes, with potential to guide new microbiome-based approaches.
-
Bioengineered brain barrier chip to improve drug screening for brain tumors
A small, patient-friendly brain barrier chip is being developed to test drugs for glioblastoma more accurately before they reach clinical trials.
-
Understanding how epigenetic changes drive pediatric brain tumor recurrence and how reversing them could help
A pediatric brain cancer research project is exploring how an epigenetic change (H3K27M) and tumor environment contribute to tumor coming back, using a reversible mouse model to study potential ways to prevent recurrence.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.